Indivior PLC (INVVY)

1 member of Congress has disclosed 1 trade in Indivior PLC (INVVY) via STOCK Act filings. The most recent disclosure was a sale by Greg Gianforte on 21 December 2018. Aggregate disclosed activity totals roughly $8K in sales (midpoint estimates from bracketed disclosure amounts).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Price data is not available for INVVY
This ticker may have been delisted, renamed, or is not publicly quoted, so no live price, statistics or chart can be shown. The congressional trades disclosed for it are listed below.

Congressional Trading Activity for INVVY

1 transactions
Compliance: 100%
Greg Gianforte21 Dec 201823 Jan 2019SaleStock$1,001 - $15,000N/A

Stock Overview

Market Data

Market Cap

$3.01B

Volume

8.1K

Beta

-0.06

P/E Ratio

-62.42

Fundamentals

EPS

$-0.35

Div. Yield

2.91%

Open

$21.65

Day Range

$21.85 – $21.85

Company Information

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
OTC · USD
Country
US
CEO
Mark Crossley
IPO Date
2015-06-09
Website
www.indivior.com

Indivior PLC, encompassing its various subsidiaries, is a pharmaceutical firm dedicated to the research, production, and global commercialization of prescription medications. These therapies primarily utilize buprenorphine to treat opioid dependence...

Earnings

Recent Quarters

Q1 202315 Jun
EPS$0.28
Q4 202231 Mar
EPS$0.31
Q3 202231 Dec
EPS$-1.27
Q2 202230 Sept
EPS$1.45
Q2 202228 Jul
EPS$0.30
Q1 202228 Apr
EPS$0.30
Q4 202116 Feb
EPS$0.15
Q3 202127 Oct
EPS$0.15
Q2 202129 Jul
EPS$0.30
Q1 202129 Apr
EPS$0.25
Q4 202018 Feb
EPS$0.15
Q3 202028 Oct
EPS$0.12
Q2 202029 Jul
EPS$0.11
Q1 202014 May
EPS-
Q3 201931 Oct
EPS$0.30
Q2 201931 Jul
EPS$0.50
Q1 20192 May
EPS$0.60
Q4 201814 Feb
EPS$0.45
Q3 20181 Nov
EPS$0.40
Q2 201826 Jul
EPS$0.45
Q1 20182 May
EPS$0.50
Q3 20172 Nov
EPS$0.30
Q2 201727 Jul
EPS$0.60
Q1 20173 May
EPS$0.55

Dividends

Dividend History

15 Jun 2016
Amount $0.4750
16 Sept 2015
Amount $0.1600

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about INVVY

Which members of Congress have traded INVVY?
1 member of Congress has disclosed 1 trade in Indivior PLC (INVVY) under the STOCK Act: Greg Gianforte.
When was INVVY most recently disclosed by Congress?
The most recent INVVY disclosure was a sale by Greg Gianforte on 21 December 2018.
What is the total disclosed congressional trading volume for INVVY?
Members of Congress have disclosed approximately $8K in INVVY sales (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in INVVY?
This INVVY page updates as soon as new STOCK Act disclosures are filed for Indivior PLC. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.